These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24313873)

  • 21. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia.
    Xie F; Mantzarlis K; Malliotakis P; Koulouras V; Degroote S; Koulenti D; Blot S; Boussery K; Van Bocxlaer J; Colin P;
    J Antimicrob Chemother; 2019 Mar; 74(3):667-674. PubMed ID: 30535122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers.
    Xu FY; Huang JH; He YC; Liang LY; Li LJ; Yang J; Yin F; Xu L; Zheng QS; Wang K
    Acta Pharmacol Sin; 2017 Nov; 38(11):1580-1588. PubMed ID: 28713157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
    Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
    Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
    Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery.
    De Smet J; Colin P; De Paepe P; Ruige J; Batens H; Van Nieuwenhove Y; Vogelaers D; Blot S; Van Bocxlaer J; Van Bortel LM; Boussery K
    J Antimicrob Chemother; 2012 Jan; 67(1):226-9. PubMed ID: 21987240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
    Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
    Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y; Shibata T; Nakagawa S; Nomura N; Mitsuyama J; Mikamo H
    Jpn J Infect Dis; 2017 Nov; 70(6):616-620. PubMed ID: 28890509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the parenteral antibiotic Ertapenem as short term prophylaxis in bariatric surgery: a pharmaco-kinetic-pharmacodynamic study in class III obese female patients.
    Borracci T; Adembri C; Accetta G; Berti J; Cappellini I; Lucchese M; Biggeri A; De Gaudio AR; Novelli A
    Minerva Anestesiol; 2014 Sep; 80(9):1005-11. PubMed ID: 24476845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
    Chung EK; Fleming MR; Cheatham SC; Kays MB
    Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.
    Tanigawara Y; Nozawa K; Tsuda H
    Eur J Clin Pharmacol; 2012 Jan; 68(1):39-53. PubMed ID: 21796376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.
    Ambrose PG; Bhavnani SM; Cirincione BB; Piedmonte M; Grasela TH
    J Antimicrob Chemother; 2003 Sep; 52(3):435-40. PubMed ID: 12917247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
    Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection.
    Goutelle S; Valour F; Gagnieu MC; Laurent F; Chidiac C; Ferry T;
    J Antimicrob Chemother; 2018 Apr; 73(4):987-994. PubMed ID: 29244077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation.
    Landersdorfer CB; Kinzig M; Hennig FF; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F; Gusinde J
    Antimicrob Agents Chemother; 2009 May; 53(5):2074-81. PubMed ID: 19223648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.